Shanghai Junshi Bioscience Co., Ltd.

This study tests a new drug called JS212, given with other cancer medicines, in 80 adults with metastatic colorectal cancer that has not been treated before. The goal is to see if the combination is safe and can shrink tumors. JS212 targets two proteins on cancer cells to try to …

This study tests a new drug called JS107 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has not responded to at least one prior therapy. About 560 participants will be randomly assigned to…

This study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow, in combination with other treatments. It is for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted thera…

This study tests a new combination therapy called JS212 in people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors or slow the disease. About 280 adults aged 18 to 75 who have not…

This study tests two experimental drugs, JS212 and JS213, in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if these drugs can shrink tumors and control the disease. About 480 adults with certain cancers like kidney, prostate, bladder,…

This study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help tumors grow. It is given alone or with another drug (JS004 or docetaxel) to 66 adults with advanced non-small cell lung cancer that got worse after standard chemotherapy and immunothera…

This study tests two new drug combinations for people with advanced triple-negative breast cancer that has come back or spread. About 80 adults aged 18-75 who have not had prior treatment for advanced disease will receive either JS207 plus 9MW2821 or JS207 plus albumin paclitaxel…